Niosomal载体中的创新荧光聚合物：一种增强癌症治疗和成像的新方法
Innovative Fluorescent Polymers in Niosomal Carriers: A Novel Approach to Enhancing Cancer Therapy and Imaging
影响因子:4.10000
分区:医学4区 / 高分子科学3区 生化与分子生物学4区 材料科学：生物材料4区
发表日期:2024 Oct
作者:
Selay Tornaci, Merve Erginer, Umut Bulut, Beste Sener, Elifsu Persilioglu, İsmail Bergutay Kalaycilar, Emine Guler Celik, Hasret Yardibi, Pinar Siyah, Oguzhan Karakurt, Ali Cirpan, Baris Gokalsin, Ahmet Murat Senisik, Firat Baris Barlas
摘要
预计在未来二十年中，癌症将成为全球与疾病相关的死亡的先驱原因，这强调了迫切需要对个性化和适应性治疗策略的需求。这些策略由于药物疗效的高度差异以及癌细胞发展抗性的趋势而至关重要。这项研究研究了使用三种创新的荧光聚合物（FP-1，FP-2和FP-3）在Niosomal载体中封装的疗法纳米技术的潜力，将治疗（化学疗法和放射疗法）与荧光成像结合在一起。对这些货物的细胞毒性作用进行了评估，该货物在三种癌细胞系（A549，MCF-7和HOB）中进行了进一步的分析，以确定其使用线性加速器（Linac）以特定剂量增强放射疗法的作用的能力。荧光显微镜用于验证其在癌细胞与健康细胞系中的摄取和定位。结果证实，这些Niosomal货物不仅改善了放射疗法的抗增殖作用，而且还证明了荧光聚合物在体外成像中的实际应用。该双重功能强调了剂量优化对最大化治疗益处的重要性，同时最大程度地减少不良反应，从而增强了癌症治疗的总体功效。
Abstract
Cancer is anticipated to become the pioneer reason of disease-related deaths worldwide in the next two decades, underscoring the urgent need for personalized and adaptive treatment strategies. These strategies are crucial due to the high variability in drug efficacy and the tendency of cancer cells to develop resistance. This study investigates the potential of theranostic nanotechnology using three innovative fluorescent polymers (FP-1, FP-2, and FP-3) encapsulated in niosomal carriers, combining therapy (chemotherapy and radiotherapy) with fluorescence imaging. These cargoes are assessed for their cytotoxic effects across three cancer cell lines (A549, MCF-7, and HOb), with further analysis to determine their capacity to augment the effects of radiotherapy using a Linear Accelerator (LINAC) at specific doses. Fluorescence microscopy is utilized to verify their uptake and localization in cancerous versus healthy cell lines. The results confirmed that these niosomal cargoes not only improved the antiproliferative effects of radiotherapy but also demonstrate the practical application of fluorescent polymers in in vitro imaging. This dual function underscores the importance of dose optimization to maximize therapeutic benefits while minimizing adverse effects, thereby enhancing the overall efficacy of cancer treatments.